SADDAN (Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans) is a rare, severe FGFR3-related skeletal dysplasia caused by the heterozygous K650M mutation. It represents an intermediate phenotype between achondroplasia and thanatophoric dysplasia, with severe skeletal features but potential for survival beyond infancy. Key distinguishing features include the presence of acanthosis nigricans (hyperpigmented, velvety skin) and developmental delay/intellectual disability, which are not typical of other FGFR3 skeletal dysplasias. The condition demonstrates how different mutations at the same codon (K650) can produce distinct clinical phenotypes.
Ask a research question about SADDAN. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: SADDAN
creation_date: '2026-02-02T00:16:36Z'
updated_date: '2026-02-17T21:53:14Z'
category: Mendelian
description: >
SADDAN (Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans)
is
a rare, severe FGFR3-related skeletal dysplasia caused by the heterozygous K650M
mutation. It represents an intermediate phenotype between achondroplasia and
thanatophoric dysplasia, with severe skeletal features but potential for survival
beyond infancy. Key distinguishing features include the presence of acanthosis nigricans
(hyperpigmented, velvety skin) and developmental delay/intellectual disability,
which
are not typical of other FGFR3 skeletal dysplasias. The condition demonstrates how
different mutations at the same codon (K650) can produce distinct clinical phenotypes.
disease_term:
preferred_term: severe achondroplasia-developmental delay-acanthosis nigricans syndrome
term:
id: MONDO:0014658
label: severe achondroplasia-developmental delay-acanthosis nigricans syndrome
parents:
- FGFR3-related skeletal dysplasia
inheritance:
- name: Autosomal dominant (de novo)
description: >
Reported cases include de novo FGFR3 mutations.
evidence:
- reference: PMID:24352917
reference_title: "Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation."
supports: SUPPORT
snippet: "Both mutations were shown to occur on the same allele (cis) and de novo."
explanation: The reported case demonstrates de novo occurrence of the SADDAN-associated mutation.
prevalence:
- population: Published literature worldwide
percentage: 7 genetically confirmed cases
notes: >-
SADDAN is an ultra-rare FGFR3 skeletal dysplasia. By the 2008 Japanese case
report, only seven genetically confirmed individuals had been described.
evidence:
- reference: PMID:19039991
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The medical history of the present case includes severe skeletal dysplasia at birth, progressive acanthosis nigricans in infancy, and severe central nervous system structural abnormalities, consisting of the absence of right cerebral hemisphere (hydranencephaly), ventricular dilatation, both indicating congenital brain malformation, and porencephaly indicating destructive brain damages. The patient is severely retarded and has suffered from intractable seizures. This is the first report of a Japanese patient and the seventh case of SADDAN syndrome confirmed genetically."
explanation: This case report explicitly states that the patient represented the seventh genetically confirmed SADDAN case.
- reference: PMID:24352917
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) is an extremely rare severe skeletal dysplasia characterized by significant developmental delay, brain structural abnormalities, hearing loss, and acanthosis nigricans."
explanation: This later report confirms that SADDAN remained an extremely rare disorder.
pathophysiology:
- name: FGFR3 p.Lys650Met mutation
conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Constitutive FGFR Activation"
description: >
A single missense mutation at codon 650 (p.Lys650Met) in FGFR3 causes SADDAN.
gene:
preferred_term: FGFR3
term:
id: hgnc:3690
label: FGFR3
downstream:
- target: Constitutive FGFR3 kinase activity
description: Lys650Met increases receptor tyrosine kinase activity.
evidence:
- reference: PMID:24352917
reference_title: "Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation."
supports: SUPPORT
snippet: "The disorder is the result of a single missense mutation at codon 650 (p.Lys650Met) in the fibroblast growth factor receptor 3 gene (FGFR3)."
explanation: The abstract states SADDAN is caused by the FGFR3 p.Lys650Met mutation.
- name: Constitutive FGFR3 kinase activity
description: >
The Lys650Met mutation causes increased constitutive FGFR3 kinase activity.
gene:
preferred_term: FGFR3
term:
id: hgnc:3690
label: FGFR3
biological_processes:
- preferred_term: fibroblast growth factor receptor signaling pathway
modifier: INCREASED
term:
id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
molecular_functions:
- preferred_term: protein tyrosine kinase activity
modifier: INCREASED
term:
id: GO:0004713
label: protein tyrosine kinase activity
downstream:
- target: Severe disturbances in endochondral bone growth
description: Constitutive FGFR3 activity disrupts endochondral bone growth.
evidence:
- reference: PMID:10053006
reference_title: "A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene."
supports: SUPPORT
snippet: "Transient transfection studies with FGFR3 mutant constructs show that the Lys650Met mutation causes a dramatic increase in constitutive receptor kinase activity, approximately three times greater than that observed with the Lys650Glu mutation."
explanation: Functional studies show Lys650Met increases constitutive FGFR3 kinase activity.
- name: Severe disturbances in endochondral bone growth
conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Impaired Endochondral Ossification and Chondrodysplasia"
description: >
The Lys650Met mutation results in severe disturbances in endochondral bone growth.
cell_types:
- preferred_term: Growth plate chondrocyte
term:
id: CL:1000217
label: growth plate cartilage chondrocyte
evidence:
- reference: PMID:10377013
reference_title: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3."
supports: SUPPORT
snippet: "The FGFR3 Lys650Met mutation results in severe disturbances in endochondral bone growth that approach and overlap those observed in thanatophoric dysplasia, type I."
explanation: The abstract links Lys650Met to severe disturbances in endochondral bone growth.
phenotypes:
- name: Severe short stature
description: >
Severe disproportionate short stature, more severe than achondroplasia but
with potential for survival beyond the neonatal period.
frequency: HP_0040281
phenotype_term:
preferred_term: Severe short stature
term:
id: HP:0003510
label: Severe short stature
evidence:
- reference: PMID:38993719
reference_title: "A case of long-term survival of SADDAN treated with growth hormone for marked short stature."
supports: SUPPORT
snippet: "We administered GH therapy for a markedly short stature."
explanation: Case report explicitly notes markedly short stature in a patient with SADDAN.
- name: Developmental delay
description: >
Delayed developmental milestones and intellectual disability are characteristic
features that distinguish SADDAN from achondroplasia and thanatophoric dysplasia.
frequency: HP_0040281
phenotype_term:
preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
evidence:
- reference: PMID:24352917
reference_title: "Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation."
supports: SUPPORT
snippet: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) is an extremely rare severe skeletal dysplasia characterized by significant developmental delay, brain structural abnormalities, hearing loss, and acanthosis nigricans."
explanation: The abstract states SADDAN is characterized by significant developmental delay.
- name: Acanthosis nigricans
description: >
Hyperpigmented, velvety, thickened skin typically in flexural areas (neck, axillae,
groin). This distinctive skin finding is not seen in achondroplasia or thanatophoric
dysplasia and is part of the defining features of SADDAN.
frequency: HP_0040281
phenotype_term:
preferred_term: Acanthosis nigricans
term:
id: HP:0000956
label: Acanthosis nigricans
evidence:
- reference: PMID:24352917
reference_title: "Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation."
supports: SUPPORT
snippet: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) is an extremely rare severe skeletal dysplasia characterized by significant developmental delay, brain structural abnormalities, hearing loss, and acanthosis nigricans."
explanation: The abstract lists acanthosis nigricans as a defining feature of SADDAN.
- reference: PMID:10377013
reference_title: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3."
supports: SUPPORT
snippet: "In addition to skeletal dysplasia, progressive acanthosis nigricans, and central nervous system structural anomalies, seizures and severe developmental delays are observed in surviving SADDAN patients."
explanation: The phenotypic analysis reports progressive acanthosis nigricans in SADDAN.
- name: Seizures
description: Seizures reported in surviving SADDAN patients.
frequency: HP_0040281
phenotype_term:
preferred_term: Seizures
term:
id: HP:0001250
label: Seizure
evidence:
- reference: PMID:10377013
reference_title: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3."
supports: SUPPORT
snippet: "In addition to skeletal dysplasia, progressive acanthosis nigricans, and central nervous system structural anomalies, seizures and severe developmental delays are observed in surviving SADDAN patients."
explanation: The phenotypic analysis reports seizures in SADDAN.
- name: Hearing loss
description: Hearing loss reported in SADDAN.
frequency: HP_0040281
phenotype_term:
preferred_term: Hearing loss
term:
id: HP:0000365
label: Hearing impairment
evidence:
- reference: PMID:24352917
reference_title: "Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation."
supports: SUPPORT
snippet: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) is an extremely rare severe skeletal dysplasia characterized by significant developmental delay, brain structural abnormalities, hearing loss, and acanthosis nigricans."
explanation: The abstract lists hearing loss as a characteristic feature of SADDAN.
- name: Hydranencephaly
description: Absence of a cerebral hemisphere reported in a SADDAN case.
frequency: HP_0040281
phenotype_term:
preferred_term: Hydranencephaly
term:
id: HP:0002324
label: Hydranencephaly
evidence:
- reference: PMID:19039991
reference_title: "[Case of a Japanese female presenting severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) syndrome with a K650M mutation in the fibroblast growth factor receptor 3 gene]."
supports: SUPPORT
snippet: "severe central nervous system structural abnormalities, consisting of the absence of right cerebral hemisphere (hydranencephaly), ventricular dilatation, both indicating congenital brain malformation, and porencephaly indicating destructive brain damages."
explanation: Case report describes hydranencephaly in a SADDAN patient.
- name: Ventriculomegaly
description: Ventricular dilatation reported in a SADDAN case.
frequency: HP_0040281
phenotype_term:
preferred_term: Ventriculomegaly
term:
id: HP:0002119
label: Ventriculomegaly
evidence:
- reference: PMID:19039991
reference_title: "[Case of a Japanese female presenting severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) syndrome with a K650M mutation in the fibroblast growth factor receptor 3 gene]."
supports: SUPPORT
snippet: "severe central nervous system structural abnormalities, consisting of the absence of right cerebral hemisphere (hydranencephaly), ventricular dilatation, both indicating congenital brain malformation, and porencephaly indicating destructive brain damages."
explanation: Case report notes ventricular dilatation (ventriculomegaly) in SADDAN.
- name: Femoral bowing
description: Femoral bowing is reported in some patients with SADDAN.
frequency: HP_0040281
phenotype_term:
preferred_term: Femoral bowing
term:
id: HP:0002980
label: Femoral bowing
evidence:
- reference: PMID:10377013
reference_title: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3."
supports: SUPPORT
snippet: "Other unusual bone deformities, such as femoral bowing with reverse (i.e., posterior apex) tibial and fibular bowing and \"ram's horn\" bowing of the clavicle, are also seen in some patients."
explanation: The phenotypic analysis reports femoral bowing in SADDAN.
- name: Tibial bowing
description: Tibial bowing is reported in some patients with SADDAN.
frequency: HP_0040281
phenotype_term:
preferred_term: Tibial bowing
term:
id: HP:0002982
label: Tibial bowing
evidence:
- reference: PMID:10377013
reference_title: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3."
supports: SUPPORT
snippet: "Other unusual bone deformities, such as femoral bowing with reverse (i.e., posterior apex) tibial and fibular bowing and \"ram's horn\" bowing of the clavicle, are also seen in some patients."
explanation: The phenotypic analysis reports tibial bowing in SADDAN.
- name: Fibular bowing
description: Fibular bowing is reported in some patients with SADDAN.
frequency: HP_0040281
phenotype_term:
preferred_term: Fibular bowing
term:
id: HP:0010502
label: Fibular bowing
evidence:
- reference: PMID:10377013
reference_title: "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3."
supports: SUPPORT
snippet: "Other unusual bone deformities, such as femoral bowing with reverse (i.e., posterior apex) tibial and fibular bowing and \"ram's horn\" bowing of the clavicle, are also seen in some patients."
explanation: The phenotypic analysis reports fibular bowing in SADDAN.
genetic:
- name: FGFR3 K650M mutation
association: Causative
gene_term:
preferred_term: FGFR3
term:
id: hgnc:3690
label: FGFR3
notes: >
The c.1949A>T (p.Lys650Met) mutation is the specific cause of SADDAN. This mutation
is at the same codon as the K650E mutation (TD2) and K650Q mutation (hypochondroplasia
variant), demonstrating how different amino acid substitutions at a single position
produce distinct phenotypes. The K650M mutation causes intermediate receptor
activation between K650Q and K650E.
evidence:
- reference: PMID:24352917
reference_title: "Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation."
supports: SUPPORT
snippet: "The disorder is the result of a single missense mutation at codon 650 (p.Lys650Met) in the fibroblast growth factor receptor 3 gene (FGFR3)."
explanation: The abstract identifies p.Lys650Met in FGFR3 as the causal mutation.
- reference: CGGV:assertion_a7daa910-8226-46cc-8a65-034c0833d9cc-2022-05-09T040000.000Z
reference_title: "FGFR3 / severe achondroplasia-developmental delay-acanthosis nigricans syndrome (Moderate)"
supports: SUPPORT
evidence_source: OTHER
snippet: "FGFR3 | HGNC:3690 | severe achondroplasia-developmental delay-acanthosis nigricans syndrome | MONDO:0014658 | AD | Moderate"
explanation: ClinGen classifies the FGFR3-severe achondroplasia-developmental delay-acanthosis nigricans syndrome gene-disease relationship as moderate with autosomal dominant inheritance.
variants:
- name: c.1949A>T (p.Lys650Met)
description: The specific mutation causing SADDAN.
treatments:
- name: Growth hormone therapy
description: Growth hormone therapy for marked short stature in SADDAN.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:38993719
reference_title: "A case of long-term survival of SADDAN treated with growth hormone for marked short stature."
supports: SUPPORT
snippet: "We administered GH therapy for a markedly short stature."
explanation: Case report documents growth hormone therapy in a SADDAN patient with marked short stature.
notes: >
SADDAN is extremely rare; one report noted only a handful of molecularly confirmed
cases at the time of publication.
Reported craniofacial/thoracic features and limb disproportion are described in
case literature but need abstract-backed PMID snippets before re-adding as phenotypes.
Supportive developmental, orthopedic, and dermatologic interventions are plausible
but currently lack abstract-backed evidence in this file.
The condition illustrates the genotype-phenotype correlations within the FGFR3
spectrum: the K650 codon is critical for receptor kinase activity, and different
substitutions produce phenotypes ranging from mild (K650Q in some hypochondroplasia)
to severe viable (K650M in SADDAN) to lethal (K650E in TD2). The presence of
developmental delay and acanthosis nigricans in SADDAN suggests tissue-specific
effects of the K650M mutation that are not seen with mutations at other FGFR3
positions.
datasets:
references:
- reference: DOI:10.1016/j.bone.2020.115579
title: Novel therapeutic approaches for the treatment of achondroplasia
findings: []
- reference: DOI:10.1172/jci83926
title: Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model
findings: []
- reference: DOI:10.1182/blood.v97.3.729
title: Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
findings: []
- reference: DOI:10.1371/journal.pone.0060264
title: Activating Somatic FGFR2 Mutations in Breast Cancer
findings: []
Disease Pathophysiology Research Report
Target Disease - Disease Name: Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) - MONDO ID: MONDO_0014658 - Category: Mendelian (autosomal dominant; monoallelic) - Primary target-gene association: FGFR3 (ENSG00000068078; HGNC:3689) (OpenTargets Search: SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans)
Pathophysiology description SADDAN is an FGFR3-driven skeletal dysplasia distinguished by a triad of severe achondroplasia, neurodevelopmental delay, and acanthosis nigricans. OpenTargets maps the disease to MONDO_0014658 and Orphanet_85165, with a single, high-confidence associated target, FGFR3, supported by multiple genetic evidence sources (including Genomics England, UniProt variants, EVA, and Orphanet). The allelic requirement is monoallelic autosomal, consistent with gain-of-function pathogenesis (OpenTargets query; Nucleic Acids Research platform description; accessed 2025; see context) (OpenTargets Search: SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans).
Causative variant and activation class - Canonical variant: FGFR3 p.Lys650Met (K650M) in the activation loop of the tyrosine kinase domain; repeatedly described as the defining SADDAN allele and a highly activating, ligand-independent gain-of-function mutation. The skeletal dysplasia spectrum caused by FGFR3 shows “graded activation” correlating mutation and clinical severity, with activation-loop Lys650 substitutions among the strongest activators (urls/years in cited works) (reintjes2013activatingsomaticfgfr2 pages 8-8, legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2). - Quote (contextualized): Publications cited in the retrieved evidence summarize that activation-loop Lys650 mutations produce “profound ligand-independent kinase activation” and that “distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype” (citations aggregated within the PLoS ONE 2013 article’s reference trail; Mar 2013; https://doi.org/10.1371/journal.pone.0060264) (reintjes2013activatingsomaticfgfr2 pages 8-8).
Core signaling mechanisms - Upstream: FGFR3 dimerization/auto-phosphorylation with activation-loop stabilization in K650M drives constitutive signaling (general FGFR3 mechanism summarized) (Feb 2001; https://doi.org/10.1182/blood.v97.3.729) (chesi2001activatedfibroblastgrowth pages 1-2). - Downstream pathways engaged by mutant FGFR3 in growth plate chondrocytes include MAPK/ERK, STAT (notably STAT1), PI3K–AKT, and PLCγ. Experimental inhibition with the FGFR inhibitor NVP-BGJ398 (infigratinib) in mouse models reduced FGFR3 phosphorylation and suppressed multiple downstream axes, including MAPK and STAT1, in ex vivo growth plate systems and chondrocyte cultures (May 2016; https://doi.org/10.1172/JCI83926) (komlaebri2016tyrosinekinaseinhibitor pages 1-3, komlaebri2016tyrosinekinaseinhibitor pages 13-14). - FGFR3 hyperactivation in growth plate cartilage is a negative regulator of endochondral bone growth, altering chondrocyte proliferation and differentiation. Reviews cited in the Bone 2020 article summarize that achondroplasia-spectrum FGFR3 mutations disrupt growth plate signaling and chondrogenesis; graded receptor activation correlates with severity (Dec 2020; https://doi.org/10.1016/j.bone.2020.115579) (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2).
Growth plate cellular effects - Proliferation and hypertrophic differentiation: FGFR3 activation shifts the balance toward growth arrest and impaired hypertrophic maturation, with SOX9 misregulation implicated in defective chondrocyte differentiation. STAT1 has been linked to increased apoptosis/reduced proliferation in mutant contexts; constitutive MEK1 activation recapitulates an achondroplasia-like phenotype independently of STAT1, underscoring a major role for MAPK signaling (May 2016; https://doi.org/10.1172/JCI83926) (komlaebri2016tyrosinekinaseinhibitor pages 13-14). These mechanisms align with the severe endochondral ossification defects in SADDAN.
Skin and nervous system involvement - Acanthosis nigricans: Although direct SADDAN-specific skin-pathway studies were not retrieved in the current evidence set, FGFR-family signaling is known to influence keratinocyte and epidermal biology. The high-level, ligand-independent activity of K650M plausibly contributes cell-autonomously to epidermal hyperplasia and melanocytic/keratinocytic crosstalk typical of acanthosis nigricans; this is consistent with the general principle that FGFR activation can drive proliferative signaling in different tissues (Feb 2001; https://doi.org/10.1182/blood.v97.3.729; conceptual extension from high-activation K650M class) (chesi2001activatedfibroblastgrowth pages 1-2, reintjes2013activatingsomaticfgfr2 pages 8-8). - Neurodevelopmental delay: FGFR3 is highly expressed in the developing central nervous system (CNS), and activating mutations alter developmental signaling programs. The Blood 2001 study highlights FGFR3 expression in developing CNS and skeletal precursors, supporting biological plausibility that highly activating K650M perturbs neurodevelopmental pathways and leads to developmental delay (Feb 2001; https://doi.org/10.1182/blood.v97.3.729) (chesi2001activatedfibroblastgrowth pages 1-2). Detailed, SADDAN-specific neural mechanistic papers were not captured by the current retrieval and represent a gap requiring targeted literature access.
Disease progression: from trigger to phenotype - Molecular trigger: monoallelic FGFR3 K650M causes high, ligand-independent kinase activation (reintjes2013activatingsomaticfgfr2 pages 8-8, legeaimallet2020noveltherapeuticapproaches pages 1-2). - Signaling cascade: constitutive autophosphorylation → MAPK/ERK, STAT (STAT1), PI3K–AKT, PLCγ activation in chondrocytes (komlaebri2016tyrosinekinaseinhibitor pages 1-3, komlaebri2016tyrosinekinaseinhibitor pages 13-14). - Cellular effects in growth plate: reduced proliferation, increased apoptosis (STAT1-associated), impaired transition to hypertrophy with persistent SOX9; net inhibition of endochondral bone elongation (komlaebri2016tyrosinekinaseinhibitor pages 13-14). - Tissue/organ outcomes: severe rhizomelic limb shortening, craniofacial dysmorphology consistent with FGFR3 GOF, narrow foramen magnum/spinal canal in severe forms; epidermal hyperplasia with acanthosis nigricans; neurodevelopmental delay tied to FGFR3 roles in CNS development (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2, chesi2001activatedfibroblastgrowth pages 1-2).
Key molecular players - Gene/protein: FGFR3 (HGNC:3689; ENSG00000068078) (OpenTargets Search: SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans). - Variant: FGFR3 p.Lys650Met (K650M), activation loop, tyrosine kinase domain (reintjes2013activatingsomaticfgfr2 pages 8-8, legeaimallet2020noveltherapeuticapproaches pages 1-2). - Downstream signaling nodes: MAPK/ERK cascade; STAT1; PI3K–AKT; PLCγ; SOX9 regulation during chondrocyte maturation (komlaebri2016tyrosinekinaseinhibitor pages 1-3, komlaebri2016tyrosinekinaseinhibitor pages 13-14). - Chemical entities with mechanistic relevance: Infigratinib (NVP-BGJ398), a pan-FGFR inhibitor that reduced FGFR3 phosphorylation and downstream signaling in preclinical models (May 2016; https://doi.org/10.1172/JCI83926) (komlaebri2016tyrosinekinaseinhibitor pages 1-3). - Primary cell types: growth plate chondrocytes (resting, proliferative, hypertrophic); keratinocytes and melanocytes in epidermis (for acanthosis nigricans); neural progenitors/neurons for neurodevelopment (chesi2001activatedfibroblastgrowth pages 1-2, komlaebri2016tyrosinekinaseinhibitor pages 13-14). - Anatomical locations: growth plate cartilage of long bones; craniofacial skeleton; epidermis; central nervous system (chesi2001activatedfibroblastgrowth pages 1-2, legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2).
Dysregulated biological processes (candidate GO annotations) - Fibroblast growth factor receptor signaling pathway; transmembrane receptor protein tyrosine kinase signaling. - MAPK cascade; ERK1/2 signaling; JAK/STAT signaling; PI3K–AKT signaling; phospholipase C-activating signaling. - Endochondral ossification; chondrocyte proliferation; chondrocyte differentiation (hypertrophic transition); regulation of apoptosis. - Epidermal cell proliferation and keratinization (by inference from FGFR signaling biology; SADDAN-specific confirmation required) (komlaebri2016tyrosinekinaseinhibitor pages 1-3, chesi2001activatedfibroblastgrowth pages 1-2, legeaimallet2020noveltherapeuticapproaches pages 5-5, komlaebri2016tyrosinekinaseinhibitor pages 13-14, legeaimallet2020noveltherapeuticapproaches pages 1-2).
Cellular components (candidate GO CC annotations) - FGFR3 localized at plasma membrane; signaling complexes in the cytosol; nuclear effectors (e.g., STAT1) after activation. Growth plate extracellular matrix is affected indirectly through altered chondrocyte maturation (komlaebri2016tyrosinekinaseinhibitor pages 1-3, chesi2001activatedfibroblastgrowth pages 1-2, komlaebri2016tyrosinekinaseinhibitor pages 13-14).
Disease progression and stages - Prenatal/early postnatal: constitutive FGFR3 signaling impairs endochondral ossification; severe limb shortening and craniofacial features evident early (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2). - Early childhood: progressive skeletal complications, foramen magnum/spinal canal narrowing risk (extrapolated from FGFR3-spectrum data), onset of acanthosis nigricans, neurodevelopmental delay manifests (legeaimallet2020noveltherapeuticapproaches pages 5-5, chesi2001activatedfibroblastgrowth pages 1-2). - Later outcomes: persistent short stature with significant functional and orthopedic burden; skin findings and neurological sequelae vary (legeaimallet2020noveltherapeuticapproaches pages 5-5, chesi2001activatedfibroblastgrowth pages 1-2).
Phenotype associations (HPO terms; mechanistic links) - Disproportionate short stature (HP:0004322), Rhizomelia (HP:0000912) due to impaired chondrocyte proliferation/hypertrophy and curtailed endochondral ossification (komlaebri2016tyrosinekinaseinhibitor pages 13-14, legeaimallet2020noveltherapeuticapproaches pages 5-5). - Macrocephaly/craniofacial dysmorphology (HP:0000256, multiple craniofacial HPOs) consistent with FGFR3 GOF effects (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2). - Developmental delay (HP:0001263) aligned with FGFR3 expression in developing CNS and potential signaling dysregulation (chesi2001activatedfibroblastgrowth pages 1-2). - Acanthosis nigricans (HP:0000956) plausibly arising from epidermal hyperproliferation driven by aberrant RTK signaling (chesi2001activatedfibroblastgrowth pages 1-2, reintjes2013activatingsomaticfgfr2 pages 8-8).
Current applications and implementations - FGFR pathway inhibition: Infigratinib (NVP-BGJ398) reduced FGFR3 phosphorylation and corrected signaling in preclinical models of FGFR3-related dwarfism, supporting target validity for pharmacologic modulation of the FGFR3 axis (May 2016; https://doi.org/10.1172/JCI83926) (komlaebri2016tyrosinekinaseinhibitor pages 1-3). This aligns with the broader therapeutic exploration of FGFR pathway modulators across diseases. - FGFR3-targeted skeletal dysplasia strategies: Reviews highlight multiple approaches to normalize growth plate signaling in FGFR3 GOF disorders, including ligand traps, FGFR inhibitors, and downstream pathway modulation (Dec 2020; https://doi.org/10.1016/j.bone.2020.115579) (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2).
Expert opinions and analysis - Bone 2020 review synthesizes FGFR3 pathobiology as a negative regulator of bone growth, emphasizing graded mutation activation and growth plate signaling derangements as central to disease; this conceptual framework supports SADDAN’s severe end of the spectrum (Dec 2020; https://doi.org/10.1016/j.bone.2020.115579) (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2). - Mechanistic breadth: Evidence across systems (developmental bone, CNS, and oncology) converges on FGFR3 as a potent RTK whose constitutive activation can drive proliferation, differentiation shifts, and survival changes depending on cellular context, explaining SADDAN’s skeletal and extra-skeletal features (Feb 2001; https://doi.org/10.1182/blood.v97.3.729) (chesi2001activatedfibroblastgrowth pages 1-2).
Relevant statistics and data - OpenTargets association scores between SADDAN and FGFR3 are high (approximately 0.72–0.82 across disease entries), with multiple genetic evidence items and PMIDs listed in the platform’s evidence set (platform updated through 2025) (OpenTargets Search: SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans). - Preclinical pharmacology: FGFR inhibitor exposure in ex vivo/murine models reduces FGFR3 phosphorylation and downstream markers (MAPK, STAT1) and functionally improves bone growth phenotypes (May 2016; https://doi.org/10.1172/JCI83926) (komlaebri2016tyrosinekinaseinhibitor pages 1-3).
Ontology-ready annotations - Gene/protein: FGFR3 (HGNC:3689; ENSG00000068078) (OpenTargets Search: SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans). - Variants: FGFR3 p.Lys650Met (K650M), canonical for SADDAN (reintjes2013activatingsomaticfgfr2 pages 8-8, legeaimallet2020noveltherapeuticapproaches pages 1-2). - Biological processes (GO BP; examples): fibroblast growth factor receptor signaling pathway; MAPK cascade; regulation of chondrocyte proliferation; chondrocyte differentiation; endochondral ossification; JAK/STAT signaling; PI3K–AKT signaling; PLC-activating signaling (komlaebri2016tyrosinekinaseinhibitor pages 1-3, legeaimallet2020noveltherapeuticapproaches pages 5-5, komlaebri2016tyrosinekinaseinhibitor pages 13-14, legeaimallet2020noveltherapeuticapproaches pages 1-2, chesi2001activatedfibroblastgrowth pages 1-2). - Cellular components (GO CC; examples): plasma membrane; cytosol; nucleus; extracellular matrix of cartilage (affected via chondrocytes) (komlaebri2016tyrosinekinaseinhibitor pages 1-3, komlaebri2016tyrosinekinaseinhibitor pages 13-14, chesi2001activatedfibroblastgrowth pages 1-2). - Cell types (CL; examples): chondrocyte (growth plate), hypertrophic chondrocyte, keratinocyte, melanocyte, neural progenitor (komlaebri2016tyrosinekinaseinhibitor pages 13-14, chesi2001activatedfibroblastgrowth pages 1-2). - Anatomical locations (UBERON; examples): growth plate cartilage of long bone; craniofacial skeleton; epidermis; brain (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2, chesi2001activatedfibroblastgrowth pages 1-2). - Chemical entities (examples): infigratinib/NVP-BGJ398 (FGFR inhibitor) (komlaebri2016tyrosinekinaseinhibitor pages 1-3). - Phenotype associations (HPO; examples): disproportionate short stature (HP:0004322); rhizomelia (HP:0000912); macrocephaly (HP:0000256); developmental delay (HP:0001263); acanthosis nigricans (HP:0000956) (mechanism-linked in text) (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2, chesi2001activatedfibroblastgrowth pages 1-2, reintjes2013activatingsomaticfgfr2 pages 8-8, komlaebri2016tyrosinekinaseinhibitor pages 13-14).
Direct quotes (from retrieved sources) - “Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.” (Title; The Journal of Clinical Investigation; May 2016; https://doi.org/10.1172/JCI83926) (komlaebri2016tyrosinekinaseinhibitor pages 1-3). - The review highlights FGFR3 as a “negative regulator of bone growth,” and that “graded activation of fibroblast growth factor receptor 3 by mutations” correlates with clinical severity across the achondroplasia spectrum (paraphrased from cited works within Bone 2020 review; Dec 2020; https://doi.org/10.1016/j.bone.2020.115579) (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2). - FGFR3 is “highly expressed in developing central nervous system and precursor bone/cartilage rudiments,” underscoring relevance to skeletal and neurodevelopmental phenotypes (Blood; Feb 2001; https://doi.org/10.1182/blood.v97.3.729) (chesi2001activatedfibroblastgrowth pages 1-2).
Limitations and evidence gaps - The current tool-based retrieval did not surface the seminal primary descriptions of SADDAN with PMID-linked full text (e.g., earliest clinical-genetic reports) nor SADDAN-specific mechanistic skin/CNS studies. Where mechanistic inferences were drawn (e.g., acanthosis nigricans and neurodevelopment), they are grounded in FGFR3 expression biology and activation-class logic but would benefit from targeted retrieval of the primary SADDAN case series and molecular dermatology/neurology studies. These should be added in subsequent updates to strengthen direct-evidence quotes and statistics (OpenTargets Search: SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans, reintjes2013activatingsomaticfgfr2 pages 8-8, chesi2001activatedfibroblastgrowth pages 1-2, legeaimallet2020noveltherapeuticapproaches pages 5-5, komlaebri2016tyrosinekinaseinhibitor pages 13-14, legeaimallet2020noveltherapeuticapproaches pages 1-2).
Citations with URLs and dates - OpenTargets Platform mapping and evidence for SADDAN→FGFR3; accessed 2025; platform methods in Nucleic Acids Research: https://www.opentargets.org/ (OpenTargets Search: SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans). - Komla-Ebri D, et al. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. The Journal of Clinical Investigation. May 2016. https://doi.org/10.1172/JCI83926 (komlaebri2016tyrosinekinaseinhibitor pages 1-3, komlaebri2016tyrosinekinaseinhibitor pages 13-14). - Reintjes N, et al. Activating Somatic FGFR2 Mutations in Breast Cancer. PLoS ONE. Mar 2013. https://doi.org/10.1371/journal.pone.0060264 (contextual references to FGFR3 K650M activation class within article’s discussion). (reintjes2013activatingsomaticfgfr2 pages 8-8). - Chesi M, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. Feb 2001. https://doi.org/10.1182/blood.v97.3.729 (chesi2001activatedfibroblastgrowth pages 1-2). - Legeai‑Mallet L, Savarirayan R. Novel therapeutic approaches for the treatment of achondroplasia. Bone. Dec 2020. https://doi.org/10.1016/j.bone.2020.115579 (legeaimallet2020noveltherapeuticapproaches pages 5-5, legeaimallet2020noveltherapeuticapproaches pages 1-2).
Overall assessment SADDAN pathophysiology is driven by a highly activating FGFR3 K650M mutation that constitutively engages MAPK/ERK, STAT1, PI3K–AKT, and PLCγ signaling in growth plate chondrocytes, disrupting proliferation and hypertrophic differentiation and promoting apoptosis, thereby severely restricting endochondral ossification. The combination of skeletal, skin, and neurodevelopmental phenotypes aligns with the breadth of FGFR3 expression and signaling roles in cartilage, epidermis, and CNS development. Preclinical FGFR inhibition restores signaling balance and bone growth in models, reinforcing the causal pathway. Further SADDAN-specific clinical-genetic series and dermatologic/neuroscience studies are recommended for more granular phenotype statistics and direct mechanistic quotations.
Support for each major claim is provided in the citations above, with URLs and publication months/years where available (OpenTargets Search: SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans, komlaebri2016tyrosinekinaseinhibitor pages 1-3, reintjes2013activatingsomaticfgfr2 pages 8-8, chesi2001activatedfibroblastgrowth pages 1-2, legeaimallet2020noveltherapeuticapproaches pages 5-5, komlaebri2016tyrosinekinaseinhibitor pages 13-14, legeaimallet2020noveltherapeuticapproaches pages 1-2).
References
(OpenTargets Search: SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans): Open Targets Query (SADDAN,severe achondroplasia with developmental delay and acanthosis nigricans, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(reintjes2013activatingsomaticfgfr2 pages 8-8): Nadine Reintjes, Yun Li, Alexandra Becker, Edyta Rohmann, Rita Schmutzler, and Bernd Wollnik. Activating somatic fgfr2 mutations in breast cancer. PLoS ONE, 8:e60264, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0060264, doi:10.1371/journal.pone.0060264. This article has 53 citations and is from a peer-reviewed journal.
(legeaimallet2020noveltherapeuticapproaches pages 5-5): Laurence Legeai-Mallet and Ravi Savarirayan. Novel therapeutic approaches for the treatment of achondroplasia. Bone, 141:115579, Dec 2020. URL: https://doi.org/10.1016/j.bone.2020.115579, doi:10.1016/j.bone.2020.115579. This article has 68 citations and is from a domain leading peer-reviewed journal.
(legeaimallet2020noveltherapeuticapproaches pages 1-2): Laurence Legeai-Mallet and Ravi Savarirayan. Novel therapeutic approaches for the treatment of achondroplasia. Bone, 141:115579, Dec 2020. URL: https://doi.org/10.1016/j.bone.2020.115579, doi:10.1016/j.bone.2020.115579. This article has 68 citations and is from a domain leading peer-reviewed journal.
(chesi2001activatedfibroblastgrowth pages 1-2): Marta Chesi, Leslie A. Brents, Sarah A. Ely, Carlos Bais, Davide F. Robbiani, Enrique A. Mesri, W. Michael Kuehl, and P. Leif Bergsagel. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood, 97 3:729-36, Feb 2001. URL: https://doi.org/10.1182/blood.v97.3.729, doi:10.1182/blood.v97.3.729. This article has 393 citations and is from a highest quality peer-reviewed journal.
(komlaebri2016tyrosinekinaseinhibitor pages 1-3): Davide Komla-Ebri, Emilie Dambroise, Ina Kramer, Catherine Benoist-Lasselin, Nabil Kaci, Cindy Le Gall, Ludovic Martin, Patricia Busca, Florent Barbault, Diana Graus-Porta, Arnold Munnich, Michaela Kneissel, Federico Di Rocco, Martin Biosse-Duplan, and Laurence Legeai-Mallet. Tyrosine kinase inhibitor nvp-bgj398 functionally improves fgfr3-related dwarfism in mouse model. The Journal of clinical investigation, 126 5:1871-84, May 2016. URL: https://doi.org/10.1172/jci83926, doi:10.1172/jci83926. This article has 118 citations.
(komlaebri2016tyrosinekinaseinhibitor pages 13-14): Davide Komla-Ebri, Emilie Dambroise, Ina Kramer, Catherine Benoist-Lasselin, Nabil Kaci, Cindy Le Gall, Ludovic Martin, Patricia Busca, Florent Barbault, Diana Graus-Porta, Arnold Munnich, Michaela Kneissel, Federico Di Rocco, Martin Biosse-Duplan, and Laurence Legeai-Mallet. Tyrosine kinase inhibitor nvp-bgj398 functionally improves fgfr3-related dwarfism in mouse model. The Journal of clinical investigation, 126 5:1871-84, May 2016. URL: https://doi.org/10.1172/jci83926, doi:10.1172/jci83926. This article has 118 citations.